Is there enough evidence now to use injectable semaglutide as a foundational therapy for symptomatic heart failure with preserved ejection fraction in the setting of overweight or obesity?

While the evidence for using injectable semaglutide in the setting of heart failure with preserved ejection fraction (HFpEF) and overweight/obesity is promising, it's still considered emerging!

• STEP-HFpEF trial: This large, well-designed study showed that semaglutide significantly improved symptoms, physical limitations, and exercise function in HFpEF patients with obesity compared to placebo. It also led to substantial weight loss and reductions in inflammatory markers.
• Other studies: Smaller studies have also suggested the benefits of semaglutide in this setting, though more research is needed.

Points to consider:

• Limited long-term data: Most studies have followed patients for only a year or less. It's unclear if the benefits of semagluti...